Document:

Exhibit 10.4

 Exhibit 10.4 
  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

RESEARCH COLLABORATION AGREEMENT 

This Research Collaboration Agreement (the “Agreement”) having an Effective Date of March 1st, 2014, is made between the
Friedrich Miescher Institute for Biomedical Research (“FMI”) located at Maulbeerstrasse 66, 4058 Basel, Switzerland, (Principal Investigator Dr. Botond Roska), and GenSight Biologics, located at 89 Rue du Fbg Saint Antoine, 75011
Paris, France (“GenSight”), (Principal Investigator Dr. Didier Pruneau), under the following terms and conditions. 
  

	 	1.	Research Project. FMI and GenSight (the “Parties”) desire to undertake collaborative research activities for the purpose of to be completed by FMI Towards this goal FMI and GenSight will exchange
material and know-how. The project will be conducted at the Roska Lab of the FMI by Dr. Tamas Szikra. GenSight shall contribute to said research work by subvention to FMI following GenSight’s receipt of an invoice. GenSight contribution
will be done according to the following scheme: 

  

	 	•	 	Issuance of credit payment to FMI for subvention of research work in March 2014: 111,240 EUR. 

  

	 	•	 	Issuance of credit payment to FMI for subvention of research work in March 2015: 111,240 EUR. 

  

	 	•	 	Issuance of credit payment to FMI for subvention of research work in March 2016: 111,240 EUR. 

  

	 	2.	Transfer of Materials and Information Among Parties. Biological and other research materials, as hereinafter defined, may be transferred between FMI and GenSight in connection with the Research Project.
The following terms shall govern any transfer of materials pursuant to the Research Project. 

  

	 	a.	In General. It is expected that materials developed outside the course of the Research Project will be exchanged between GenSight and FMI. In addition, other materials developed during the course of the
Research Project may be transferred between the Parties, as agreed upon by the aforementioned principal investigators, as part of the Research Project under the terms of this Agreement. The original research material provided by FMI and any progeny
and unmodified derivatives and any additional materials transferred between the Parties under this paragraph 2a shall be owned solely by FMI (“FMI Materials”). The original research material provided by GenSight and any progeny and
unmodified derivatives and any additional materials transferred between the Parties under this Paragraph 2a shall be owned solely by the Institution (“GenSight Materials”). Materials developed jointly by researchers at FMI and GenSight in
the course of the Research Project will be owned jointly by GenSight and FMI (“Jointly Developed Materials”). All such materials are sometimes hereinafter referred to as Research Materials, singly or collectively. 

  
 1 

	 	b.	Research Materials. All Research Materials transferred in connection with the Research Project are experimental in nature and shall be used with prudence and appropriate caution, since not all of their
characteristics are known. ALL RESEARCH MATERIALS ARE PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. A Party providing its Research Materials (the
“Provider”) makes no representation or warranty to the receiving party (the “Recipient”) that the use of such Research Materials will not infringe any patent or other proprietary right. However, FMI, to the best of its knowledge
and experience, represents and warrants to GenSight that there are no rights or obligations owed by FMI to any third party that may restrict or impair GenSight’s use of the FMI Materials as contemplated by this Agreement 

Novartis Pharma AG has certain rights in Research Results developed by FMI under the Research and Proprietary Rights Agreement (RPRA),
effective as of January 1, 2012. 
  

	 	c.	Legal Title; Use. Legal title to any Research Materials transferred hereunder shall be unaffected by this Agreement or the transfer made hereunder. GenSight will use FMI Materials only in work done in the
course of the Research Project, and only in the laboratory of GenSight’s Principal Investigator in research by laboratory personnel under that Principal Investigator’s immediate and direct control. In addition, during the term of the
Research Project, any Jointly Developed Materials will not be used by the Parties other than in the Research Project. 

  

	 	d.	Limitations. Research Materials transferred under this Agreement are provided only for use in animals or in vitro. Research Materials transferred under this Agreement will not be used
in humans, including for purposes of diagnostic testing. Any use of Research Materials by the transferee, other than in accordance with this paragraph 2, is a material breach of this Agreement for purposes for the termination
provisions of paragraph 8, below. 

  

	 	e.	Recipient Rights in Transferred Materials. The transfer of Materials between FMI and GenSight gives the Recipient no rights in such material other than those specifically set forth in this
Agreement. 

  

	 	3.	 Confidentiality. Subject to paragraph 5, below, during the term of this Agreement and for a period of five years thereafter, Recipient
shall cause all information that is disclosed to it by Provider in connection with the Research Project and that is identified in writing as confidential by Provider (“Confidential Information”), to be treated according to the same
internal security procedures and with the same degree of care regarding its secrecy and confidentiality as Recipient treats similar information of its own. Confidential Information does not include information that (i) is or later becomes
available to the public through no fault of Recipient or its representative; (ii) is obtained from a third party who had the legal right to disclose the information; (iii) as of the date of disclosure, is already in the possession of
Recipient (and such prior possession can be properly demonstrated by Recipient); (iv) is required to be disclosed 

  
 2 

	 	
by law, government regulation, rule, act or court order (but only to the extent so required); or (v) is independently developed by Recipient (and such independent development can be properly
demonstrated by Recipient). 

  

	 	4.	Results of Research Project. 

  

	 	a.	In General. Each Party will submit the research results obtained from its work in connection with the Research Project to the other Party. Information shared in accordance with this paragraph
shall be treated as Confidential Information by the Recipient (even if not identified as Confidential Information by Provider) and shall be handled by Recipient in accordance with the procedures set forth in paragraph 3, above. Each Party and its
Affiliates shall have an unrestricted right to use for its own internal non-commercial research purposes all research results, including without limitation any Sole Invention of any Party and any Joint Invention (as such terms are defined below),
obtained from the Research Project. 

 b. Inventions. For the purpose of determining ownership under this
paragraph, inventorship of Inventions will be determined in accordance with principles of U.S. patent law. An “Invention” is any invention or discovery, whether patentable or non-patentable, or
copyrightable or non-copyrightable, that is conceived or reduced to practice in the course of and during the performance of the Research Project by at least Dr. Tamas Szikra. In the case of a non-patentable Invention, inventorship will be
determined under such principles by treating such Invention as if it were patentable. Subject to paragraph 2a, if an Invention is made by one or more inventors all of whom are required to assign rights in the Invention to a single Party (a
“Sole Invention”), the Sole Invention shall be the property of that Party. If an Invention is made by more than one inventor, and at least one inventor is required to assign rights in the Invention to FMI and at least one inventor is
required to assign rights in the Invention to GenSight, the Invention shall be jointly owned by the Parties who are assigned rights in the Invention (a “Joint Invention”). GenSight and FMI may pursue joint patent protection of Joint
Inventions. If either Party chooses not to file a patent application, it may relinquish its rights to the other Party. Thereafter, the other Party may file the patent application in its own name, and at its own expense. In any event, the
relinquishing Party and its Affiliates shall retain all research use licenses granted herein. “Affiliates” shall mean any entity or subsidiary which controls a Party. For purposes of this definition, “control” or
“controlled” shall mean ownership directly or through one or more Affiliates, of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or fifty percent
(50%) or more of the equity interest in the case of any other type of legal entity, status as a general partner in any partnership, or any other arrangement whereby a Party controls or has the right to control the Board of Directors or
equivalent governing body of a corporation or other entity, or the ability to cause the direction of the management or policies of a corporation or other entity. The Parties acknowledge that in the case of certain entities organized under the laws
of certain countries outside of the US, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such case such lower percentage shall be substituted in the preceding sentence,
provided that such foreign investor has the power to direct the management and policies of such entity. 

  
 3 

	 	c.	Options and Rights of Novartis. Under conditions detailed in and in line with the RPRA, Novartis Pharma AG and Affiliates, shall have an option to obtain at the sole discretion of Novartis Pharma AG, a
worldwide, non exclusive license with the right to grant sub licenses to Affiliates of Novartis Pharma AG to make, have made use and sell any FMI Sole Inventions or the FMI share of any Joint Inventions. 

 

	 	d.	Options and Rights of Gensight Biologics. 

 Gensight Biologics shall have an
option to obtain at its sole discretion a worldwide, non exclusive license with the right to grant sub licenses to its Affiliates to make, have made use and sell any FMI Sole Inventions. 

In case Novartis Pharma AG does not exercise its option (according to paragraph c) to obtain a worldwide, non exclusive license on any FMI Sole
Inventions, then Gensight Biologics shall have an option to obtain at its sole discretion a worldwide, exclusive license with the right to grant sub licenses to its Affiliates to make, have made use and sell any FMI Sole Inventions. 

 

	 	e.	Reports 

 Annual report will be provided to GenSight of study progress,
publications and patents submission on the anniversary date. 
  

	5.	Publication. The Parties will consult with one another about how best to manage external publications of collaborative work and will cooperate in coordinating external presentations of any research results
obtained under this Agreement. Authorship of results of the Research Project will be determined in accordance with academic standards and custom. Proper acknowledgement will be made for the contributions of each Party to the research results being
published. If a proposed publication is not a joint publication, the Party wishing to make the publication shall provide a copy of the manuscript or abstract to the other Party at least [**] days prior to submission of the manuscript or abstract for
publication in order to allow the other Party an opportunity to protect proprietary information or intellectual property that might be disclosed by the manuscript or abstract. In addition, a Party will not publish Confidential Information received
from the other Party without such other Party’s prior written consent. 

  

	6.	Responsibilities of the Parties. Except to the extent prohibited by law, each Party is responsible and liable to the other Party only for its own acts and omissions, and the acts and omissions of its
trustees, directors, officers, employees, and agents, relating to the Research Project or to any Research Materials that have been transferred to it in connection with the Research Project. The Parties agree to indemnify and hold each other and its
respective trustees, directors, officers, employees, and agents harmless from any claim, liability, cost, expense, damage, deficiency, loss or obligation, of any kind or nature (including without limitation, reasonable attorneys’ fees)
(collectively, “Claims”) resulting from the other Parties acts or omissions, or those of its trustees, directors, officers, employees, or agents, under, arising out of or otherwise related to this Agreement, the Research Project or the
Research Materials transferred in connection with the Research Project, except to the extent such Claim arises out of the gross negligence or intentional wrongdoing of the Party seeking indemnification or that of its trustees, directors, officers,
employees or agents. 

  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 4 

	7.	Compliance with Laws and Regulations. All research done in connection with the Research Project, including all use of Research Materials transferred hereunder, will be done in compliance with all laws,
governmental regulations and guidelines. 

  

	8.	Term of Agreement: Duration of Research Project. This Agreement shall go into effect on the Effective Date. This Agreement shall continue in effect until February 28th, 2017. In the event of a
material breach of this Agreement by a Party, the non-breaching Party may terminate the Research Project and this Agreement following 15 days’ written notice to the other Party and failure to cure the
breach by the breaching Party during such 15 day period. If the Research Project and this Agreement are terminated, GenSight Materials and Confidential Information received pursuant to this Agreement by FMI shall, at the request of GenSight, be
returned to GenSight or properly destroyed. The terms of paragraphs 2, 4, 5, 6, 9, 10 and 15 and of paragraph 3 as specified therein, and of this sentence and the preceding sentence, shall survive any termination of this Agreement.

   

	9.	Assignment. This Agreement is not assignable by a Party, whether by operation of law or otherwise, without the prior written consent of the other Party, except to an Affiliate of such Party. Any attempt to
assign in violation of this Section 9 shall be void and without effect. 

  

	10.	Governing Law. This Agreement shall be governed by and construed in accordance with the law of Basel-Stadt, Switzerland. 

 

	11.	Independent Parties. GenSight and FMI shall, at all times, act as independent Parties and nothing contained in this Agreement shall be construed or implied to create an agency, partnership or other joint
enterprise between the Parties. 

  

	12.	Severability. If any one or more of the provisions of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining provisions of this
Agreement shall not in any way be affected or impaired thereby. 

  

	13.	Notices. Any notice or communication provided for in this Agreement to be made by either of the Parties to the other shall be in writing, in English, and shall be made by prepaid registered or certified
mail with return receipt or by express overnight courier addressed to the other at its address set forth below. Notices shall be sent: 

  

			
	If to FMI, to:	 	Dr. Nicolas Favre
		
		 	Head Patents & Licensing
		
		 	Friedrich Miescher Institute for Biomedical Research Maulbeerstrasse 66
		
		 	 CH-4058 Basel
  

Switzerland

		
		 	Fax: +41 61 697 53 23

  
 5 

			
		
	If to GenSight, to:	 	GenSight Biologics
		
		 	89 Rue du Fbg Saint Antoine 75011 Paris, France
		
		 	Attention: Didier Pruneau

  

	14.	Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument. 

 

	15.	Entire Agreement. This Agreement between the Parties sets forth all of the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with
respect to the Research Project, and supersedes all previous written and oral communications. No amendment, alteration or modification of this Agreement or any exhibits attached hereto shall be valid unless executed in writing by authorized
signatories of both Parties. 

  

			
	GenSight Biologics	  	Friedrich Miescher Institute for Research
	/s/ Bernard Gilly	  	/s/ Prof. Dr. Susan Grasser
	Title: CEO	  	Title: Director
		
		  	/s/ Dr. Nicolas Favre
		  	Title: Head Patents & Licensing
		
		  	 Read and Acknowledges:

		  	/s/ Dr. Botond Roska
		  	Title: Group Leader

  
 6 

 Summary of Research Project: 

[**] 
  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 7Exhibit 10.6

 Exhibit 10.6 
  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

CONSORTIUM AGREEMENT 

SIGHT AGAIN 

Projet de R&D Structurant Pour La Compétitivité 

BETWEEN: 
 GenSight Biologics, a French public limited
company (“Société Anonyme”) with share capital of €218,867.23, whose head office is at 89 Rue du Faubourg St Antoine, 75011 Paris, registered in the Paris Trade and Companies Register under number 751 164 757 000
21, represented by Jean Philippe Combal in his capacity as Chief Operating Officer (COO), who has power of signature, hereinafter referred to as “GenSight”; 

AND 
 Pixium Vision, a French public limited company
(“Société Anonyme”) with share capital of €477,873.24, whose head office is at Institut de la Vision, 13 Rue Moreau, 75012 Paris, registered in the Paris Trade and Companies Register under number 538 797 655 000
23, represented by Bernard Gilly in his capacity as Chairman and Chief Executive Officer, who has power of signature, hereinafter referred to as “Pixium”; 

AND 
 Fondation Voir et Entendre, a scientific cooperation
foundation, whose head office is at Centre Hospitalier des Quinze-Vingts, 28 Rue de Charenton, 75012 Paris, represented by Jean Charles Pomerol, acting in the capacity of Chairman in accordance with the powers granted to him, hereinafter
referred to as “FVE”; 
 Hereinafter referred to jointly as the “Parties” and individually as the
“Party”. 

 Contents 
  

					
	 1 – DEFINITIONS
	  	 	4	  
		
	 2 – OBJECT OF THE CONSORTIUM AGREEMENT
	  	 	6	  
		
	 3 – ORGANIZATION OF THE WORK
	  	 	6	  
		
	 4 – LIABILITY AND INSURANCE
	  	 	11	  
		
	 5 – CONFIDENTIALITY
	  	 	13	  
		
	 6 – PUBLICATIONS & COMMUNICATIONS
	  	 	14	  
		
	 7 – OWNERSHIP OF THE KNOWLEDGE AND RESULTS
	  	 	15	  
		
	 8 – USE OF THE RESULTS
	  	 	17	  
		
	 9 – ENTRY INTO EFFECT, TERM AND TERMINATION
	  	 	19	  
		
	 10 – DEFAULT AND EXPULSION OF A PARTY
	  	 	20	  
		
	 11 – NOTICES
	  	 	21	  
		
	 12 – GENERAL PROVISIONS
	  	 	21	  
		
	 13 – DISPUTES
	  	 	23	  
		
	 SCHEDULES
	  	 	25	  

 WHEREAS: 

The collaborative project entitled “Sight Again”, hereinafter referred to as the “Project”, has been selected to receive financing
within the framework of Projets de R&D Structurants pour la Compétitivité. 
 The aim of the Sight Again project is to restore
sight to people suffering from blindness and defined as legally blind, following damage to the retina including the loss of photoreceptor cells. 
 The
project includes three partners: two French companies, GenSight Biologics and Pixium Vision, and a public research body, Fondation Voir et Entendre. 

The partners intend to collaborate on the Project for a period of five years, with a view to developing two complementary therapeutic products designed to
restore sight: an optogenetic gene therapy product, GS020, and a sight restoration system including a retinal implant, PRIMA. 
 The Parties who are
receiving financing in relation to the Project have jointly signed a master agreement with Bpifrance (hereinafter referred to as the “Operator”), which sets forth the Parties’ obligations in consideration of the award of the funding
and the manner in which this funding will be paid. 
 In this consortium agreement, the Parties specify the overall framework of their collaboration. 

 NOW, THEREFORE, THE PARTIES AGREE AS FOLLOWS: 

1 – DEFINITIONS 
 Capitalized terms
used in the remainder of the agreement have the following meanings: 
  

	•	 	Consortium Agreement: this agreement, including any schedules and amendments hereto. 

  

	•	 	Shared Patent: a patent application or a registered patent on a Shared Result. 

  

	•	 	Knowledge: any knowledge of any kind and in any form, held or developed by a Party, including technical and scientific knowledge, experience, know-how, manufacturing and trade secrets, patents, patent
applications, methods, tools, procedures, specific components, plans, diagrams, drawings, protocols, formulas, Materials, biological materials, software (in its source-code and object-code version) and
Information, regardless of whether they are or could be protected by a right and/or intellectual property title. 

  

	•	 	Prior Knowledge: any Knowledge held or developed by a Party prior to signing this Consortium Agreement. 

  

	•	 	Parallel Knowledge: any Knowledge held or developed by a Party in parallel to and independently of the Project, namely without using the Shared Results, another Party’s Proprietary Results or Information
belonging to another Party and covered by the provisions of clause 5 (Confidentiality) below. 

  

	•	 	Proprietary Knowledge: all Prior Knowledge and Parallel Knowledge. The Proprietary Knowledge used as part of the Project is listed in Schedule 4, which may be supplemented during the execution of the Project via
a signed amendment pursuant to the provisions of clause 12.6 hereof. 

  

	•	 	Contribution: any contribution of an inventive, intellectual (including a contribution of Information) and/or material (including financial) nature made by Party in order to obtain a Result, without which this
Result would not have been obtained. 

  

	•	 	Coordinator: the Party responsible for the proper running of the Project, i.e. GenSight. 

  

	•	 	Field: has the following respective meanings for each Party: 

 In the case of Pixium: a
sight restoration system, including an implant that enables the retina to be stimulated electronically, and a vision stimulation device which enables this system to be activated and which may be combined with a device designed to configure the
system and support the rehabilitation of patients who have received implants. 
 In the case of GenSight: treatment of patients suffering
from retinal dystrophy using gene therapy, specifically via an optogenetic approach, which may or may not involve a vision stimulation device. 
  

	•	 	Affiliate: any legal entity that: 

  

	 	•	 	controls a Party directly or indirectly; 

  

	 	•	 	or is under the same direct or indirect control as a Party; 

  

	 	•	 	or is directly or indirectly controlled by a Party. 

 A legal entity shall be considered to control another legal entity: 

 

	 	•	 	where it directly or indirectly holds at least fifty per cent (50%) of the share capital of this legal entity or over fifty per cent (50%) of the voting rights of the legal entity’s shareholders;

  

	 	•	 	or where it effectively holds the power of decision over that legal entity, either directly or indirectly. 

The rights granted to the Parties under the terms of this Consortium Agreement shall only extend to their Affiliates in the case of legal
entities that were classified as Affiliates at the time when said rights were exercised. If a legal entity is declassified as an Affiliate during the term of the Consortium Agreement, the rights acquired by the said legal entity in its capacity as
an Affiliate shall lapse immediately, unless specified in writing by the Parties. A legal entity that ceases to be classified as an Affiliate shall nonetheless remain subject to all obligations pursuant to the Consortium Agreement, which shall
remain in force and effect due to its nature, and specifically to the obligations regarding Information set forth in clause 5. In any event, each Party shall remain liable for the due performance of obligations hereunder by its Affiliates. 

 

	•	 	Working Group: all Scientific Representatives of the Parties involved in a given Package. 

  

	•	 	Information: any technical, scientific, operating or commercial information or data generated or exchanged by the Parties, regardless of the form in which it is held. Where applicable, the Information may relate
to Proprietary Knowledge or to the Results. 

  

	•	 	Package: a series of tasks entrusted to one or more Parties and clearly identified in Schedule 1. 

  

	•	 	Project Manager: the Party appointed to manage and monitor the Shared Results, in accordance with the terms and conditions set forth in clause 7. 

 

	•	 	Materials: shall be assigned the definition provided in clause 4.4 below. 

  

	•	 	Operator: the party responsible for monitoring the implementation of the project, i.e. Bpifrance in this case. 

  

	•	 	Project Section: the Project Tasks assigned to a Party in accordance with Schedule 1. 

  

	•	 	Project: the research and development project entitled Sight Again, which has been selected for financing as part of the Projet structurant des Pôles de Compétitivité, or PSPC,
program. The Project is set out in Schedule 1 hereto. 

  

	•	 	Scientific Representative: the representative for each Party who is responsible for the proper performance of the Tasks incumbent on that Party. 

 

	•	 	Package Manager: the Party’s representative who is responsible for the proper execution of a Package. 

  

	•	 	Result: any information, of any kind and in any form, obtained by one or more Parties during the execution of the Project, including Knowledge, experience, know-how, manufacturing and trade secrets, patents,
patent applications, methods, tool designs, procedures, specific components, plans, diagrams, drawings, protocols, formulas, biological or chemical products or equipment, other products or equipment such as mechanical or electronic devices (in any
form including prototype form), software (in its source-code and object-code version) and Information, regardless of whether they are or could be protected by a right and/or intellectual property title. 

	•	 	Shared Result: a Result obtained within the framework of the Project through the joint and inseparable Contribution of at least two Parties. 

 

	•	 	Proprietary Result: a Result obtained independently by a single Party within the framework of the Project, without the Contribution of another Party. 

 

	•	 	Subcontractor: any Third Party to whom a Party assigns the task of carrying out all or part of a Package on behalf of and under the responsibility of that Party. 

 

	•	 	Tasks: the tasks relating to one or more Package(s) entrusted to a Party. 

  

	•	 	Third Party: any individual or legal entity that is neither a Party nor a Party’s Affiliate. 

 It
is understood that any term in the singular shall include the same term in the plural, and vice versa. 
 2 – OBJECT OF THE
CONSORTIUM AGREEMENT 
 The purpose of the Consortium Agreement is to define the organization of the work between the Parties, determine the
procedures for implementing the Project and define the Parties’ rights and obligations. The Consortium Agreement is specifically intended to determine the procedures for transferring and using the Proprietary Knowledge exchanged, managing and
protecting the Results, sharing the intellectual property rights and to define the joint ownership and project management rules governing the Shared Results. 

The execution of the Project shall be shared between the Parties in accordance with the assignment of the Tasks as defined in the Project set out in Schedule
1. 
 The cooperation established in this way shall not exclude any cooperation with Third Parties, either on a joint basis within the framework of the
Consortium Agreement or separately involving any of the Parties outside this framework. 
 3 – ORGANIZATION OF THE WORK

  

	3.1	Organization of the Project 

 The Project shall be coordinated by the Coordinator. Any decision relating
to the execution of the Project shall be taken by the Steering Committee. 
 The Project is divided into Packages. Each Package shall be coordinated by a
Package Manager working together with a Working Group comprising the Scientific Representatives of the Parties involved in the Package and any other members of these Parties’ staff who are required for the Project. 

Each Party shall execute the Project Section that has been assigned to it (and shall specifically deliver the deliverables) under its sole responsibility, in
particular vis-à-vis the Operator, in accordance with the timetable. Each Party undertakes to assign the staff and resources required for the execution of their Project Section, in accordance with the Project as accepted for financing. Each
Party shall remain exclusively liable for any related expenditure that is not covered by the public financing package. Each Party shall be responsible for obtaining any authorizations and making any disclosures required for the execution of their
Project Section. 

 Each Party undertakes to fulfill their obligations in good faith, in accordance with industry best practices and
applicable laws and regulations and with respect towards the other Parties’ brand image and reputation. Each Party undertakes to perform the Work incumbent on them in compliance with statutory provisions and applicable best practices (including
Best Laboratory Practices and Best Manufacturing Practices). 
 Each Party shall be required to inform the Coordinator and the Steering Committee of any
problem encountered during the execution of their Project Section that could compromise the Project’s objectives, within a period of [**] days, in accordance with the Working Group procedures set out in clause 3.6. 

A Party may subcontract all or part of their Project Section to a Third Party under the conditions set out in clause 12.8. 

The Results shall be recorded, according to their nature, by the persons with the relevant responsibility listed in clauses 3.3, 3.4 and 3.5. Without
prejudice to the application of legal specifications and best practices that provide for different timeframes and provisions, the gross data for the Project shall be recorded by each of the Parties involved in the Working Groups in administration
logs kept in their respective archives, as described in clause 3.6, which may be consulted by any other Party upon prior request. Each Party shall archive all the documents relating to the Project (including electronic files) for a period of at
least [**] years as from the end of the experimental phase of the Project. In the event that a Party is no longer able to retain its gross results, it shall inform the Coordinator and the other Parties, who shall determine the new conditions for
retaining these gross results by joint agreement. 
  

	3.2	Steering Committee 

 A steering committee (hereinafter referred to as the “Steering
Committee”) shall be set up to monitor the execution of the Project. 
  

	3.2.1	Composition 

 The Steering Committee shall include the Project Coordinator and a representative
from each Party. 
 The representatives appointed by each Party are listed in Schedule 2. Each Party may change its representative after
informing the Coordinator, without the need to sign an amendment. Each Party may be accompanied by no more than three persons from within their organization whose presence may be required by the agenda. 

The Steering Committee may also request the attendance of external personnel and/or experts where necessary in accordance with the agenda.
Third Party attendees shall be accepted on the prior condition that each member of the Steering Committee has been informed and that said participant has signed a confidentiality agreement beforehand. 

[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

	3.2.2	Scope of operation 

 The Steering Committee’s scope of operation shall specifically
include: 
  

	 	•	 	monitoring the satisfactory performance of the Project and the Packages, working together with the Package Managers; 

  

	 	•	 	approving the Results and Information produced by the Working Groups prior to disclosure thereof to the Operator; 

  

	 	•	 	refocusing the Packages on the recommendation of the Package Managers; 

  

	 	•	 	the amendment or suspension of all or part of the Project; 

  

	 	•	 	approving amendments to this Consortium Agreement; 

  

	 	•	 	the decision to admit a new Party to the Project; 

  

	 	•	 	the decision to expel a Party, in the event that said Party fails to execute the Tasks incumbent upon it, in accordance with the procedures set out in clause 10; 

 

	 	•	 	settlement, as far as possible, of any conflicts that may delay the completion of the Project; 

  

	 	•	 	coordinating downstream operations (publication, protection and exploitation). 

  

	3.2.3	Operation 

 The Coordinator shall convene the Steering Committee on an annual basis, and may
convene it at any time in the event of an exceptional situation or at the request of one of the Parties, as often as the interests of all the Parties shall require, via a written request to the Parties. The agenda must be forwarded to the members of
the Steering Committee at the addresses for notice specified in clause 11 at least [**] days prior to the date of the meeting. Each Party may request that an item be entered on the agenda. The agenda shall be drawn up by the Coordinator, after
consulting the Parties. 
 The Steering Committee shall take its decisions on a unanimous basis. Only the Parties’ representatives shall
have the right to vote. The Coordinator, together with any other persons who have been invited, as determined in clause 3.2.1, shall not be entitled to vote. 

The Committee’s decisions may include the following issues, without limitation: refocusing the Packages on the recommendation of the
Package Managers, and amending or suspending all or part of the Project. 
 In the case of any decision related to a Party’s failure to
execute and the expulsion of that Party, the Party concerned shall not be entitled to vote. However, that Party shall be heard by the other Parties, if they so wish, and shall have the opportunity to enter any written comments in the minutes of the
discussions. The Steering Committee shall be empowered to rule on the expulsion of a Party only if this issue is expressly included on the agenda. The expulsion shall only become final once it has been approved by the Operator, to whom the Parties
requesting the expulsion shall forward the minutes of the meeting. 
 The Parties agree to abide by any decisions taken by the Steering
Committee. No additional responsibility or charge may be imposed on a Party without its consent. Except in the event of expulsion determined in accordance with the foregoing terms, no right can be withdrawn from a Party without their consent. 

Any decision taken by the Steering Committee that is liable to affect this Consortium Agreement must be the subject of an amendment. 

The discussions of the Steering Committee shall be set down in minutes drafted by the Coordinator and approved in turn by one of the
representatives of each Party, by tacit agreement. These minutes shall be forwarded to each Party at the addresses for notice specified in clause 11 and a copy shall be sent to the Operator. Unless written comments are made within [**] days as from
the date when the minutes are forwarded, the Parties shall be assumed to have accepted all the statements included in those minutes. This report may not be considered as amending the provisions of the Agreement, or as increasing or restricting the
Parties’ rights and obligations arising therefrom, as such variations may only be made via an amendment to the Agreement. 

  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

	3.3	Coordinator 

 The Coordinator shall be appointed when this Agreement is signed and shall be mentioned in
Schedule 3. This individual shall be a member of the company that is identified as the project leader as defined by BPI, namely GenSight Biologics in the case of the Sight Again project. 

A new Coordinator may be appointed by GenSight Biologics. The partner who employs the Coordinator must inform all members of the Steering Committee of this
new appointment within [**] days following the change. 
 The Coordinator shall be responsible for: 

 

	 	•	 	the general administration of the Project; 

  

	 	•	 	forwarding any documents and information regarding the Project to the Parties concerned and to the members of the Steering Committee; 

 

	 	•	 	convening the Steering Committee; 

  

	 	•	 	circulating the confidential scientific reports to the Parties’ representatives on the Steering Committee and to the Operator; 

  

	 	•	 	circulating the minutes of Steering Committee meetings; 

  

	 	•	 	informing the Parties of any replacement of a Party’s representative on the Steering Committee; 

  

	 	•	 	recording any documents and results relating to the steering and administration of the Project, and any other responsibilities included in their duties. 

The Coordinator shall be the preferred contact person for the Package Managers and the Scientific Representatives, so as to enable close monitoring of the
satisfactory performance of the Packages and liaising with the Steering Committee. 
 The Coordinator shall also be the Operator’s preferred contact
person responsible for monitoring progress on the completion of the Project. The Coordinator shall be responsible for forwarding any documents and information relating to the Project to the Operator on request. 

 

	3.4	Package Managers 

 Each Package Manager shall be appointed by the Party with whom they are associated.
The name of each Package Manager is provided in Schedule 3. 
 Each Party may appoint a new Package Manager to replace the previous incumbent as and when
required. The Party responsible shall inform the Coordinator of this new appointment within [**] days. The Coordinator shall take charge of forwarding this information to the project members. 

The Package Managers shall be responsible for: 
  

	•	 	managing the progress of the Package for which they are responsible; 

  

	•	 	submitting to the Steering Committee any proposal for refocusing the Packages put forward by the Working Groups; 

  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

	•	 	forwarding a detailed written report on the progress of the Package and on any problems encountered to the Coordinator before each Steering Committee meeting, within a period of no less than [**] days prior to the
holding of the meeting; 

  

	•	 	informing the Coordinator of any delay in the progress of the Package for which they are responsible as soon as possible and, at the latest, within [**] days; 

 

	•	 	forwarding any information to the Coordinator required by the latter in order to fulfill their assignment, including any information required by the Coordinator to respond to the Operator’s requests;

  

	•	 	recording any documents and results relating to the Package for which they are responsible, and any other responsibilities included in their duties. 

 

	3.5	Scientific Representatives 

 Each Scientific Representative shall be appointed by the Party with whom
they are associated. The name of each Scientific Representative is provided in Schedule 3. 
 Each Party may appoint a new Scientific Representative to
replace the previous incumbent as and when required. The Party responsible shall inform the Coordinator of this new appointment within a period of [**] days. The Coordinator shall take charge of forwarding this information to the project members.

 The Scientific Representatives shall be responsible for: 
  

	 	•	 	managing the progress of the Tasks for which their Party is responsible on a day-to-day basis; 

  

	 	•	 	informing the Package Managers and the Coordinator of any delay in the progress of the Tasks for which the Party they represent is responsible; 

 

	 	•	 	obtaining any documents and administrative authorizations required for their Party’s participation in the Project; 

  

	 	•	 	attending the Working Groups; 

  

	 	•	 	forwarding any information to the Coordinator and Package Managers that the latter require in order to fulfill their assignments, in particular to enable the Coordinator to respond to the Operator’s requests;

  

	 	•	 	recording any administration logs relating to their activities as part of the Project, and any documents and results for which they are responsible and that relate to any other responsibilities included in their duties.

  

	3.6	Working Groups 

 Each Working Group shall consist of the Scientific Representatives for each Party
involved in a given Package and shall be steered by a Package Manager. 
 The Working Groups shall act as a discussion platform (Information, Results,
Materials, etc.) and a platform for monitoring the Packages (approval of Results, review of the Package, etc.). The role of the Working Groups shall be to: 
  

	 	•	 	guarantee the satisfactory performance of the Package for which they are responsible; 

  

	 	•	 	approve the Results, and issue an opinion on their operational applications; 

  

	 	•	 	identify any delay or technical problem in the execution of the Packages and inform the Coordinator thereof; 

  

	 	•	 	make suggestions to the Steering Committee regarding the refocusing of the Packages; 

  

	 	•	 	review, approve and make recommendations to the Steering Committee on the plans to publish or protect the Results; 

  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

	 	•	 	implement the Steering Committee’s decisions and recommendations; 

  

	 	•	 	record any documents, administration logs and other documents and results for which they are responsible and which relate to any other responsibilities included in their duties. 

4 – LIABILITY AND INSURANCE 
  

	4.1	Responsibilities relating to the execution of the Project 

 Each Party shall be responsible for the
satisfactory performance of the Tasks entrusted to it, in accordance with the Project, as agreed and set out in Schedule 1, and for any loss suffered by the other Parties as a result of their failure to fulfil their obligations under the terms
of the Consortium Agreement. 
 Each Party shall be responsible for the regulatory and certification stages incumbent upon it in accordance with the
satisfactory performance of the Tasks for which they are responsible, as described in the Project agreed and set out in Schedule 1. 
 The Parties
waive their reciprocal rights to request compensation for any indirect losses, such as financial or commercial losses that are not the direct and immediate consequence of a breach of their obligations by a Party (including loss of production or use,
benefits, or anticipated business and loss of earnings etc.) and/or non-material losses. No Party may be held responsible for the other Parties’ actions or omissions. The provisions of the Consortium Agreement shall not give rise to any joint
and several liability between the Parties. 
 Each Party shall bear the expenses relating to the execution of the Tasks incumbent upon it within the
timeframes specified, in accordance with the Project as agreed for financing, and set out in Schedule 1. The procedures for releasing and managing said financing shall be the subject of specific agreements between each Party and the Operator. 

 

	4.2	Provisions relating to staff 

 A Party’s employees or individuals acting on their behalf may be
required to work at the premises of another Party as part of the execution of the Project. The staff shall need to have been clearly identified, and shall retain the status of the original organization that manages them in accordance with its own
rules and procedures and the applicable legislation, which shall fulfill its responsibility towards them as an employer, specifically where medical surveillance programs and professional training is concerned. 

A Party’s employee or individuals acting on their behalf and carrying out operations at another Party’s premises shall be required to comply with
the confidentiality, discipline, and health and safety rules in effect at those premises. They shall be informed of these rules before they commence operations. The staff concerned by specific instructions for a work station shall be informed of
those instructions by the manager of the host organization. 
 Provisions relating to staff shall be governed by the provisions of French law applicable in
this area. 

	4.3	Provisions relating to insurance 

 Each Party shall be responsible, where it is concerned, for insuring
its employees or individuals acting on its behalf and involved in the Project, in accordance with the employment and occupational health legislation applicable to them, and shall perform the legal formalities incumbent upon it. 

Accordingly, compensation for any harm suffered by these employees or individuals shall be paid under the terms of the aforementioned legislation and their
particular status. 
 Each Party shall be responsible for the damage that its employees or individuals acting on its behalf may cause to persons or goods,
during, or a result of the performance of the Consortium Agreement, including any damage resulting from the use of materials or equipment belonging to another Party, under the conditions of ordinary law. 

Each Party acknowledges, in view of its status and where it is concerned, that it is its own insurer, or that it is responsible for taking out and maintaining
the insurance policies required to cover its liabilities as part of the execution hereof. 
  

	4.4	Provisions relating to the forwarding of information 

 Each Party shall be exclusively responsible for
losses, without any claim against other Parties of any kind that arise as a result of (or during) their use of the Information or material forwarded by another Party by any means, i.e. orally or in the form of documents of any kind, regardless of
their format. 
 Any transfer of a Party’s (hereinafter referred to as the “Supplier”) materials (biological or chemical products or
equipment, or other materials, specifically including mechanical or electronic devices in their final form or in prototype form, hereinafter referred to as the “Materials”) to another Party (hereinafter referred to as the
“Recipient”) shall be free of charge, and shall be subject to the following terms and conditions: 
  

	•	 	The Materials shall remain the Supplier’s property, notwithstanding the provisions of clause 7 below; 

  

	•	 	The Recipient shall not be granted any right to market the Materials under the terms hereof, without prejudice to the provisions of clause 8 below. 

 

	•	 	The Recipient undertakes that the Materials: 

  

	 	•	 	shall only be used to execute the Project, excluding any other use; 

  

	 	•	 	shall not be given or forwarded to a Third Party for any purpose; 

  

	 	•	 	shall only be used in accordance with the laws and regulations applicable to these kinds of Materials; 

  

	 	•	 	shall be used exclusively on the Recipient’s premises and by scientists working in the Recipient’s laboratories, or under their direct responsibility; 

 

	•	 	The transfer of Materials shall not prevent or delay publication of the research results resulting from use of the Materials. Any publication relating to the use of the Materials shall take place in accordance with
clause 6 below; 

  

	•	 	The Recipient shall accept the Materials as is, and acknowledges that they are of an experimental nature and must therefore be used with prudence and precaution, since not all of their characteristic features are known.
THE SUPPLIER SHALL NOT TAKE MEASURES AND SHALL NOT PROVIDE ANY EXPRESS OR TACIT WARRANTY OF ANY KIND. LIKEWISE, THE SUPPLIER OR THE INVENTORS SHALL NOT PROVIDE ANY EXPRESS OR TACIT WARRANTY REGARDING THE MATERIALS’ COMMERCIAL POTENTIAL, OR
THEIR APPROPRIATENESS FOR A PARTICULAR PURPOSE, OR AGAINST ANY OFFENCE; 

 The Supplier (and their directors, employees and representatives) shall not assume any liability,
and shall not take any measures where the Materials or their use by the Recipient are concerned. The Recipient shall defend, compensate and hold the Supplier harmless against any losses, claims, or liability that may arise from the use of the
Materials or the related Information. 
  

	•	 	The Recipient undertakes to take charge of the transfer, storage and all other formalities relating to the transfer of the Materials. 

 

	•	 	The transfer of the Materials shall not be interpreted as an assignment or license to use said Materials granted by the Supplier to the Recipient. Specifically, the Recipient undertakes to consult the Supplier, in order
to decide on the ownership and the potential conditions for using the Results that may arise from the Recipient’s use of the Materials, in accordance with clause 7 and clause 8 hereof. 

The Supplier may ask the Recipient to sign the receipt set forth in Schedule 5 or any equivalent document, in order to ensure traceability of the transfer of
the Materials. 
 5 – CONFIDENTIALITY 
  

	5.1	Each Party undertakes not to publish or disclose, via any means, any Information of which they may become aware during the execution hereof and which belongs to another Party and has been identified as confidential by
the latter. In addition, each Party shall refrain from using said Information for any other purposes than that of executing the Project. 

  

	5.2	The Parties undertake to keep all the Information of which they may become aware as part of the execution of the Project secret, and not to refer to that Information regardless of the means of communication without the
prior written consent of the Party or Parties from which the Information emanates, in accordance with the procedures provided for in clause 6. 

  

	5.3	Each Party undertakes to ensure that all of their staff involved in the execution hereof comply with this confidentiality obligation. This confidentiality obligation shall remain in force throughout the term of this
Consortium Agreement, and beyond that term for a period of [**] years following its expiry or termination. However, in the event that the Information relates to know-how, these obligations shall remain in effect without any limits on the timeframe
and until the said know-how is disclosed by the Party who owns it, or by a Third Party who is not bound by a confidentiality obligation. 

The situation would only be different: 
  

	•	 	in the case of Information that has already been publicly disclosed prior to the execution hereof, or Information of which public disclosure would not result in a breach of the confidentiality obligation as set down in
this clause by the Party to whom it has been disclosed; 

  

	•	 	in the case of Information that one of the Parties has received or may receive in the future from a Third Party who is not specifically bound by a confidentiality agreement with the Party who owns the information;

  

	•	 	in the case of Information that was already in the possession of one of the Parties prior to its disclosure by the Party who owns that information; 

  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

	•	 	in the case of Information for which disclosure is required as the result of an injunction by the authorities in the healthcare field. In this case, the Party that has received the information shall consult the Party
who owns the Information prior to any disclosure of the Information; 

  

	•	 	in the case of Information that the Party who owns the Information expressly authorizes the Party who receives that information to disclose. 

 

	5.4	However, the provisions of this clause shall not prevent: 

  

	 	•	 	either the obligation that may be incumbent on one Party’s staff to produce a business report intended for a financing organization or for the organization to which it is attached, to the extent that this
communication does not amount to a disclosure within the meaning of industrial property law; this report must specify that it is of a confidential nature, 

  

	 	•	 	or the defense of a thesis, in the event that the Parties have agreed to allow Ph.D. students to take part in the Project. However, if required, the Parties shall make every effort to obtain an exemption from the
President of the University or institution concerned, in order for the thesis to be defended in camera; this defense process shall be organized each time that it is required in order to guarantee the confidentiality of certain research.

  

	5.5	The Parties shall grant their consent for the provisions in this clause to include the Information relating to the Project that may have been forwarded or made known to them or to their staff via any means as from [**].

 6 – PUBLICATIONS & COMMUNICATIONS 

Any draft publication or verbal or written communication by one of the Parties relating hereto, or that is directly or indirectly related to all or part of the
Results must be submitted for the opinion of the other Parties during the term of this Consortium Agreement and during the [**] months following its expiry or termination; the other Parties shall make their decision known within a maximum period of
[**] working days as from the request. Once this period has expired and if there is no response, the other Parties’ consent shall be deemed to have been granted. 

Any change or objection to a publication or communication request must be expressed to the Coordinator and to the Party or Parties concerned in writing, and
must be based on duly justified grounds, such as: 
  

	 	•	 	the failure to mention the objecting Party as the joint author; 

  

	 	•	 	the risk of disclosure of confidential information belonging to the objecting Party; 

  

	 	•	 	any threat to the industrial property protection of a Result belonging to the objecting Party that has not yet been protected. 

Any deletion or amendment must not jeopardize the scientific value of the publication. 

If information contained in the publication or communication is required to be subject to industrial property protection, the planned publication may be
delayed for a maximum period of [**] months as from the initial date suggested for publication. Some Results may be kept secret, following the written agreement of each Party, or at the request of the French Government. The Parties involved shall
determine the portion of the Results included in the confidential file, and the period during which that file shall remain secret. The other information may be published under the conditions provided for above. 

  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

 7 – OWNERSHIP OF KNOWLEDGE AND RESULTS 

 

	7.1	Proprietary Knowledge 

 Proprietary Knowledge, specifically including each Party’s Materials and
Information, shall remain the exclusive property of said Party. Each Party may use another Party’s Proprietary Knowledge free of charge exclusively for the Tasks incumbent upon them, and excluding any other use. 

 

	7.2	Results 

  

	7.2.1	The Proprietary Results shall be the property of the Party that obtained them. This Party shall protect those Results at its own expense. The Party must inform the Coordinator that it has obtained industrial protection
for its Proprietary Results as soon as possible. The Coordinator shall inform the other Parties at a Steering Committee meeting. The forwarding of this information shall be handled in accordance with clause 5. 

 

	7.2.2	Each Party shall inform the Coordinator of any Shared Result. The Coordinator shall inform all the other Parties at a Steering Committee meeting. The forwarding of this information shall be handled in accordance with
clause 5. 

 The Shared Results shall be jointly owned by the Parties involved in obtaining said Results. Said Parties’
share in the joint ownership of said Results shall be equal to their respective Contributions on a proportional basis. Said Parties shall provide all the material items required to assess their Contributions, pursuant to clause 5, and shall
determine their joint ownership shares after discussing them in good faith. Their agreement shall be formally set down in a “letter of agreement” signed by their respective representatives. If said Parties cannot reach an agreement
regarding the determination of the joint ownership shares, the shares shall be determined in accordance with the provisions of Sub-Paragraph 2 of clause 8.3.1. 
  

	7.2.3    	

  

	7.2.3.1	In the event that the Parties decide to protect a Shared Result by a Shared Patent, the Parties shall appoint the Coordinator as the Project Manager, as long as the latter is a joint holder of the shared Patent. If this
is not the case, the Parties that jointly hold the Shared Patent shall appoint the Project Manager by mutual agreement. The Project Manager shall manage and monitor the Shared Patent, including the various procedural extensions, such as the right of
priority attached to the Patent, its country extensions, and its extensions relating to terms, divisions, continuation, re-issuance, and objections, as from when the first patent application is initially filed until the date when it enters the
public domain. The Parties undertake to negotiate joint ownership regulations, on the understanding that the following have already been agreed: 

  

	 	•	 	A) The filing, maintenance, extension and defense expenses shall be paid by the Parties who are the joint holders of the Shared Patents and who have a right to use that Patent for commercial purposes, in accordance with
the provisions of clause 8.3.1 below. These expenses shall be considered as advances on the remuneration for use payable to the joint holder(s) of the Shared Patent who do not use it. If no compensation is payable due to lack of use, these expenses
shall be considered as foregone advances; 

	 	•	 	B) the procedures for filing, maintaining, extending and defending the Shared Patent shall be determined by mutual agreement between the Parties who are the joint holders of the Shared Patent, on the understanding that
the Parties who are the joint holders of the Shared Patent and have the right to use that Patent for commercial purposes in accordance with the provisions of clause 8.3.1 shall each have a right of veto, which is exclusively intended to protect
their industrial interests; 

  

	 	•	 	C) patent protection shall be sought for the Shared Results that may appear patentable, in the United States and five countries that are members of the European Convention on Patents at the least; 

 

	 	•	 	D) any joint ownership share held by a joint holder of the Shared Patent who has a right to use that patent for commercial purposes in accordance with the provisions of clause 8.3.1 can only be assigned to a Third Party
along with the asset class to which the Shared Patent is attached. Such assignment shall not be subject to any pre-emption right for the benefit of the other joint holders. Any other assignment of a Shared Patent shall be subject to the pre-emption
right specified in the provisions of Article L. 613-29 e) of the French Intellectual Property Code. 

  

	 	•	 	E) The conditions for using the Shared Results are set out in clause 8.3.1 below. 

  

	7.2.3.2	The Parties that are the joint owners undertake: 

  

	 	•	 	to disclose to one another all the technical and administrative documents required to file and obtain Shared Patents; 

  

	 	•	 	to ensure that the names of the inventors are mentioned in the Shared Patents, in accordance with the legal provisions in effect; 

  

	 	•	 	to ensure that all their staff who are mentioned as the inventors provide all the signatures and perform all the formalities required for filing, obtaining, maintaining and defending the Shared Patents, in particular
when they sign an assignment of rights relating to the U.S. procedure. 

 Each Party shall be responsible for any remuneration
that may be payable to the inventors and/or authors whom it employs. 
  

	7.2.4	In the event that one of the Parties who is a joint holder waives their right to apply for a Shared Patent, the other Party or Parties who are the joint owners may submit the application in their name only and at their
expense, while the other joint owners shall remain bound by the undertakings in clause 7.2.3.2 above. 

 8 – USE OF THE RESULTS 

 

	8.1	Use for research purposes 

 Each Party may use its Results (its Proprietary Results and the Shared
Results that it jointly owns) freely and without charge for their own internal research purposes with a view to acquiring knowledge, but excluding research conducted for the benefit of Third Parties. 

 

	8.2	Use of another Party’s Proprietary Knowledge and Results 

 If one of the Parties’ use of its
Results in its Field requires the use of Proprietary Knowledge or Proprietary Results that are partly or fully owned by another Party, the latter shall grant the Third Party a non-exclusive usage license in accordance with terms and conditions to be
negotiated in good faith on a case-by-case basis, and resulting in a written deed, subject to the rights granted to Third Parties and to their legitimate interests, and subject to the provisions of clause 8.3 below. This license shall be limited to
the Field of the receiving Party. Moreover, it has been agreed that GenSight and Pixium, who shall have a right to use the products developed in the context of the Project, the “psychometric scale” system, or the PRO (Patient Reported
Outcomes) developed by FVE as part of the Sight Again Project. 
 GenSight and Pixium shall each benefit from a right of first review over FVE’s
Proprietary Results in their Field, as part of the Sight Again Project. Accordingly, FVE may not offer a Third Party any right to use its Proprietary Results without having presented these Proprietary Results to GenSight and Pixium beforehand, and
having given them the opportunity to negotiate reasonable operating conditions. 
 GenSight and Pixium shall determine, in a separate deed, the licenses for
their Proprietary Results that they intend to grant one another in their Respective Fields in order to achieve optimal use of the Results. 
  

	8.3	Use of the Shared Results 

  

	8.3.1	Shared Patents and jointly-owned Know-How 

 Notwithstanding any provision to the contrary,
GenSight and Pixium shall be named the joint and exclusive users of the Shared Results in their respective Fields. GenSight and Pixium shall each have the right to license this joint and exclusive usage right to Third Parties in their respective
Fields. In exchange for this exclusive right, and in the event that these Shared Results are used for commercial and promotional purposes, GenSight and Pixium shall repay the compensation for the use of any Shared Results that may be owned jointly
by FVE to the latter. This compensation amount shall be calculated in the form of a royalty (the Royalty) based on the revenues generated by the direct and/or indirect commercial use of said Shared Patents by GenSight and Pixium (hereinafter the Net
Sales). This Royalty shall be paid after deducting the advances paid to manage and defend the Shared Patents concerned, and after deducting shipping, insurance, and packaging expenses, and any other standard charges in this area. 

The amount of this Royalty shall be discussed by the Parties in good faith, and may not exceed zero point six percent (0.6%), and an annual cap
amounting to fifty thousand euros (€50,000) per company, on the understanding that the obligation to pay the Royalty shall be cancelled when the aggregate amount of these annual payments has reached five hundred thousand euros (€500,000).

 The cap shall be assessed individually for each Party that uses the Shared Results. If they
cannot reach an agreement, the Parties shall refer to arbitration by a mutually acceptable Third Party, or a Thirty Party appointed by the Presiding Judge of the relevant District Court (‘Tribunal de Grande Instance’) or any other
authority on whose name the Parties have agreed, in the event of a deadlock. The arbitration judgment issued by this Third Party shall be final, and their expenses shall be shared equally by the Parties concerned. 

GenSight and Pixium shall report to FVE annually on the efforts that they have made and the results that they have achieved in terms of
developing the Shared Patents. This report shall specifically mention the technical progress made, the regulatory stages achieved, and any information demonstrating the use of these Shared Results in order to market and promote the products. The
annual report shall be accompanied by the payment of the compensation amount, where applicable. 
 GenSight and Pixium shall determine, in a
separate deed, the licenses for their Shared Results that they intend to grant one another in their Respective Fields in order to achieve the optimal use of the Results. 

If none of the Parties who are a joint owner wishes to or is able to use the Shared Patents in accordance with the usage principles determined
by the Parties who are joint owners, the Project Manager shall inform the other Parties, so that they can apply to use said Shared Patents. The Parties who are not joint owners shall then declare their interest within a period of [**] months as from
receipt of the notice sent by the Project Manager. If Parties who are not joint owners have declared their interest in obtaining rights to use the Shared Patents, the terms and conditions (including the financial terms) of this usage shall be set
out in a specific written deed on a case-by-case basis. 
 If no Party wishes to or is able to use the Shared Patents in accordance with the
usage principles determined by the Parties who are joint owners, the Project Manager shall be responsible for seeking Third Parties for the use of said Shared Patents, once the Steering Committee has approved this measure. In this case, a licensing
agreement shall be drawn up between the Parties who are the joint owners of the Shared Patents and the licensees. This agreement shall be negotiated by the Project Manager, and shall be submitted to the other Parties who are the joint owners for
approval. 
 All of the provisions above shall apply to the Shared Results that are not the subject of a Shared Patent, mutatis
mutandis. 
  

	8.3.2	Trademarks 

 Each Party shall remain the owner of the trademarks and other distinctive signs
that they own. Only that Party may use them. The other Parties shall not be authorized to use them, unless an express usage license is registered with the National Trademark Registry. 

Any decision to seek protection by filing the trademark of a product or service relating to the Project shall be the responsibility of the
Steering Committee, which shall determine the filing conditions (potential joint ownership and allocation of the filing and maintenance fees). 
  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

 The Parties shall question the benefit of filing an equivalent domain name each time that a
trademark is filed jointly. If the Parties decide to file a domain name, and to the extent that a domain name cannot be filed jointly, the filing shall be performed by the Coordinator in their name, but on behalf of the Parties. 

 

	8.3.3	Assignment of literary and artistic property rights 

 In the case of Results that are
intellectual works protected by copyright (including software and computer developments, databases and research, etc.), the Parties who are the authors of said Results shall assign all or part of the copyright to the other Parties for the purpose of
executing the terms of the agreement, as and when required; this assignment shall be the subject of a future agreement once the requirements have been assessed. 
  

	8.3.4	Shared Software Results 

 Each Party who is a joint owner of property use and reproduction
rights, including rights to any current and future media, adaptation, translation, and marketing rights to that software, either on a direct basis or under license, for all countries and throughout the term of said rights, shall own the percentage
owed to them, in accordance with the provisions of clause 8.3. The aforementioned joint ownership regulations shall include all the provisions required for the full effect hereof. If one of the Parties who is the joint owner of the software in
question wishes to assign their property rights, the other Parties who are the joint owners shall have a right of pre-emption. 
 9
– ENTRY INTO EFFECT, TERM AND TERMINATION 
  

	9.1	Entry into effect 

 This Consortium Agreement shall enter into effect on the date when it is signed by
all the Parties. 
  

	9.2	Term 

 This Consortium Agreement shall remain in effect for a period of five years and six months, unless
it is terminated during its execution period under the conditions provided for in clause 9.3 below. It may be renewed by way of an amendment with the Parties’ express consent. 

Notwithstanding the fact that the Consortium Agreement has reached its expiry date, or has been terminated early in respect of some or all of the Parties, the
provisions regarding confidentiality (clause 5), publications and communications (clause 6), ownership of the Results (clause 7) and liability shall remain applicable to all the Parties, including the Parties expelled in the event of default in
accordance with clause 10. 
  

	9.3	Termination 

 This Consortium Agreement may be terminated via a unanimous decision of the Parties taken
at an extraordinary meeting of the Steering Committee. 

 10 – DEFAULT AND EXPULSION OF A PARTY 

 

	10.1	In the event that one of the Parties fails to fulfil any of their contractual obligations under the terms of this Consortium Agreement, the Party or Parties who wish to invoke this breach must inform the Coordinator
within a period of [**] days, and refer the matter to the Steering Committee. The finding regarding the breach shall be put to a vote at the Steering Committee in accordance with the procedures set out in clause 3.1. In the event that the breach is
acknowledged, the expulsion of the defaulting Party shall become effective [**] months after the Coordinator has sent a registered letter with acknowledgement of receipt setting out the grounds for the complaint, unless the defaulting Party has,
within that timeframe, fulfilled its obligations or provided proof of an impediment resulting from a force majeure event, and as long as this situation does not continue beyond a period of [**] calendar days. 

 

	10.2	A Party deemed to have been expelled ipso jure: 

  

	 	•	 	in the event that one of the Parties is the subject of court-ordered reorganization or liquidation proceedings; 

  

	 	•	 	in the event of discontinuation of business activities, dissolution, or amicable liquidation of one of the Parties. 

  

	10.3	The application of this clause shall not release the defaulting Party from fulfilling their contractual obligations until the date when the exclusion enters into effect. 

 

	10.4	The defaulting Party must fulfil the obligations undertaken, including paying any amounts due, until the termination enters into effect. In addition: 

 

	 	(i)	it shall immediately and without charge forward a report that includes all the Results and the Work it has performed up until the termination date to the other Parties and to their potential replacement, and shall
remain responsible for that report; 

  

	 	(ii)	it shall leave the facilities, equipment, and services that have been the subject of financing under the Consortium Agreement available to the other Parties, under conditions yet to be defined; 

 

	 	(iii)	it shall no longer have any right to the licenses that have been granted to them by the other Parties, and to the latter’s Proprietary Knowledge or Results; these licenses shall expire immediately and automatically
on the effective termination date; 

  

	 	(iv)	it shall maintain the following for the benefit of the other Parties: a) the licenses granted for its Proprietary Knowledge and for the Results of which it is a joint owner, or where applicable, the sole owner, for the
execution of the Project, in accordance with the terms agreed in the Consortium Agreement and in any applicable joint ownership regulations, and b) the right to obtain the licenses for their Proprietary Knowledge, subject to their prior commitments
to Third Parties, and for the Results of which it is a joint owner or, where applicable, the sole owner, which are required to use said Results, while the scope of any payment for these rights shall be negotiated in good faith. 

 

	10.5	Any expulsion of a Party must be the subject of an amendment to this Consortium Agreement. The Coordinator shall be responsible for informing the Operator. 

 

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

 11 – NOTICES 

Any notice required under the terms of this Consortium Agreement shall be sent via registered letter with acknowledgement of receipt to the Party concerned at
the following address: 
  

			
	For GenSight Biologics:	  	For Pixium Vision:
	ATTN: Jean Philippe Combal	  	ATTN: Bernard Gilly
	GenSight Biologics	  	Pixium Vision
	89 rue du Faubourg Saint Antoine	  	13 rue Moreau
	75011 Paris	  	75012 Paris
		
	For Fondation Voir et Entendre:	  	
	ATTN: Jean Charles Pomerol	  	
	Fondation Voir et Entendre	  	
	Centre Hospitalier des Quinze Vingts	  	
	28 rue de Charenton	  	
	75012 Paris	  	

 12 – GENERAL PROVISIONS 

 

	12.1	Severability 

 If one or more provisions of this Consortium Agreement are deemed to be invalid, or ruled
as such, pursuant to a law or regulation – and specifically the law of the European Union – or a final decision issued by a court with jurisdiction, the other provisions shall retain their full effect and scope and the Parties shall make
the requisite amendments without delay, while complying as far as possible with the agreement of intent that existed at a time when the Consortium agreement was signed. 
  

	12.2	Assignment – Intuitu Personae 

 None of the Parties may assign all or part of
this Consortium Agreement to a Third Party without the other Parties’ prior written consent. 
 In the event of a merger, absorption, disposal,
transfer of business activities to a Third Party or any other change in one of the Parties resulting in a change in the intuitu personae features taken into account for the signing of this Consortium Agreement, the Consortium Agreement may
only be transferred with the prior written consent of all the Parties, within a reasonable timeframe and in good faith, so as not to disrupt the change affecting the Party in question. 

In any event, the consent referred to in the previous two paragraphs must be granted within a period of 30 calendar days. After the expiration of this period,
consent shall be deemed as granted. Moreover, this consent may only be refused if written evidence is provided showing that such a disposal would jeopardize public policy and/or the financial interests of the Party undergoing the disposal. 

It is understood that said Third Party shall be subject to the same obligations as those required of the Party concerned under this Agreement, unless the
Parties agree otherwise with said Third Party. 

 In any event, an amendment to this Consortium Agreement between the Parties and said Third Party must be drawn up
at the same time as the transaction performed with the Party concerned by the disposal; this amendment shall determine the respective obligations of the new parties, in accordance with the previous paragraph. 

Notwithstanding any provisions to the contrary, it has been agreed that this clause shall not apply in the event of a public offering of the share capital of
one of the Parties and shall not apply to any change in a Party’s intuitu personae status relating to an investment in that Party’s share capital by a financial shareholder (as opposed to an industrial shareholder); these
transactions shall remain free and exempt from any formalities with regard to the other Parties. 
  

	12.3	Conflicts of interest 

 No person involved in the Project may use the Information exchanged in order to
take any measures likely to put their Party in a situation where their financial interests are in conflict with those of another Party. This provision shall apply throughout the term of the Project and during a two-year period following the
completion of the Project. 
 Each Party undertakes to ensure that all of their staff involved in the Project comply with this requirement and to assume
full liability to the other Parties for any breach thereof. 
  

	12.4	Force majeure 

 Each Party shall be excused for a breach of obligations and shall not be held liable or
required to pay compensation to the other Parties if such breach is the result of a force majeure event. However, if the force majeure event lasts for more than [**] calendar days, any of the other Parties may request the termination of the
Agreement pursuant to the provisions of clause 10. 
  

	12.5	Independent contracting parties 

 This Consortium Agreement must not be construed as establishing a de
facto partnership or corporate relationship between the Parties under any circumstances. Each Party must be considered as an independent contracting party. 
  

	12.6	Amendments 

 This Consortium Agreement cancels and supersedes any prior agreement between the Parties
relating to its subject-matter. This Consortium Agreement may only be supplemented or altered via an amendment. All amendments shall be approved unanimously by the Steering Committee. 

 

	12.7	Forbearance 

 In the event that one of the Parties breaches their obligations arising from this
Consortium Agreement, and if the non-defaulting Party fails to assert its rights resulting from said breach, the non-defaulting Party’s failure to assert their rights shall not be construed as a waiver of those rights in the future or at the
time of a further similar breach of obligations arising under this Consortium Agreement by the defaulting Party. 

  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

	12.8	Subcontracting 

 Any use of subcontracting shall take place under the exclusive responsibility of the
Party concerned, who shall be required to inform the Coordinator within thirty (30) days. In any event, said Party shall remain solely liable to the Coordinator and the other Parties for the full execution of its Tasks under the terms of the
Consortium Agreement. 
 Each Party undertakes to contractually require its Subcontractors to comply with the provisions of the Consortium Agreement. 

Each Party shall take all the measures required to comply with the rights granted to the other Parties under the Consortium Agreement in its relations with
its Subcontractors, specifically by acquiring the intellectual property rights to the Results obtained by said Subcontractors as part of the Project. 

13 – DISPUTES 
 This
Consortium Agreement is governed by the laws of France. 
 If any difficulties arise in relation to the interpretation or performance hereof, the Parties
shall submit such difficulties to the Operator and shall endeavor to resolve them amicably. 
 If any disagreement lasts more than [**] months following the
submission of the dispute to the Operator, the Parties may submit their disagreement to arbitration in order to obtain a final ruling, in accordance with the WIPO Accelerated Arbitration Regulations. The place of arbitration shall be Paris. The
arbitration proceedings shall be held in French. The dispute, disagreement or claim shall be decided in accordance with French law. 
  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

 Executed in Paris on July 11, 2014 

In as many counterparts as there are Parties 
  

					
	GenSight Biologics	 		 	Pixium Vision
			
	Chief Operating Officer (COO)	 		 	Chairman and CEO
	Jean Philippe Combal	 		 	Bernard Gilly
	/s/    Jean Philippe Combal        	 		 	/s/    Bernard Gilly        
			
	Fondation Voir et Entendre	 		 	
			
	Chairman	 		 	
	Jean Charles Pomerol	 		 	
	/s/    Jean Charles Pomerol        	 		 	

 Stamps of each Party’s Scientific Representatives: 

 

					
	GenSight Biologics	 		 	Pixium Vision
			
	CSO	 		 	CTO
	Didier Pruneau	 		 	Guillaume Buc
	/s/    Didier Pruneau        	 		 	/s/    Guillaume Buc        
			
	Fondation Voir et Entendre	 		 	
			
	CSO	 		 	
	Serge Picaud	 		 	
	/s/    Serge Picaud        	 		 	

 SCHEDULES 

Schedule 1: Overview of the Project per Package, allocation of Tasks per Party 

SIGHT AGAIN: restoring sight to the blind 
 The aim of the
Sight Again project is to restore sight to persons suffering from blindness and defined as legally blind following damage to the retina, including the loss of photoreceptor cells. The project includes three partners: two French companies,
GenSight Biologics and Pixium Vision, and a public research body, Fondation Voir et Entendre. 
 The partners intend to collaborate for
a period of five years, with a view to developing two complementary therapeutic products designed to restore sight: an optogenetic gene therapy product, GS020, and a sight restoration system including a retinal implant, PRIMA. 

[**] 
   

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

 Schedule 2: Members of the Steering Committee 

The members of the Steering Committee were as follows on the date when this Consortium Agreement was signed. 

 

			
	Representative for GenSight Biologics	  	[**]
	  
 Representative for Pixium Vision
	  	  
 [**]

 
  

	  
 Representative for Fondation Voir et Entendre
	  	  
 [**]

 
  
  

	  
 Project Coordinator
	  	  
 [**]

 
  
  

   

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

 Schedule 3: Appointment of individuals involved in the Project (Coordinator, Package Managers and Scientific
Representatives) 
  The various project members were as follows on the date when this Consortium Agreement was signed: 

 

			
	Project Coordinator	  	 [**]
  

		
	Package 1 Manager - GS020	  	 [**]
  

		
	Package 2 Manager - PRIMA	  	 [**]
  

		
	Package 3 Manager - Sight Rehabilitation Program	  	 [**]
  

		
	Package 4 Manager – Approval of information glasses	  	 [**]
  

		
	Scientific Representative for GenSight Biologics	  	 [**]
  

		
	Scientific Representative for Pixium Vision	  	 [**]
  

		
	Scientific Representative for Fondation Voir et Entendre	  	 [**]
  

   [**] 
   

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

 Schedule 4: PROPRIETARY KNOWLEDGE MADE AVAILABLE TO THE PARTIES 

GENSIGHT 
 With regard to the GS020, GenSight has licenses
for the following intellectual property rights: 
 [**] 

GenSight also has know-how relating to the GS020 product, and its production and use, specifically: 

 

	 	•	 	know-how relating to administration and usage conditions; 

  

	 	•	 	know-how relating to the production, classification and storage of pharmaceutical materials 

 [**] 

PIXIUM 
 Pixium Vision has a large portfolio of patents in
the fields of retinal implants and sight restoration. 
 In the case of the PRIMA product, Pixium has licenses for the following intellectual property
rights: 
 [**] 
 FVE 

FVE has know-how including: 
 [**] 

FVE has the following prior knowledge: 
 Pixium & GenSight

 [**] 
 Pixium 

[**] 
 GenSight 

[**] 
   

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

 Schedule 5: SUPPORTING DOCUMENT FOR THE TRANSFER OF BIOLOGICAL MATERIALS 

As part of the Consortium Agreement that entered into effect on
                     and was signed by: 
 Party 1 Ref:

 Party 2 Ref: 
 The Issuing Party (defined below) hereby
gives its consent for the transfer of the Biological Materials (described below) to the Recipient Party (defined below) for the execution of the Project under the terms and conditions of the Consortium Agreement signed on
    /    /             
   

			
	Biological Materials	 	 Name:
  

 
  

Quantities:
  

 

		
	Party supplying the Biological Materials (the “Issuing Party”)	 	  
  

		
	Name and address of the party supplying the Biological Materials	 	  
  

 

	Contact details of the scientist supplying the Biological Materials	 	 Name:
  

Email address:
  

Tel:
  

Fax:
  

		
	Party receiving the Biological Materials (the “Recipient Party”)	 	  
  

	Delivery address for the Biological Materials	 	 Address:
  

 
  

		
	Name of the recipient	 	  
 Email address:
                                         
                                   

Tel:                         
                                         
                         

Fax:                         
                                         
                            

   Executed in two (2) counterparts drafted in French, one (1) for each Party. 

 

					
	On behalf of XXX	 		 	On behalf of XXX
	Executed in
                                         
                           	 		 	Executed
in                                        
                            
	On     /    /            	 		 	On     /    /

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}]]